21 Worrying Reasons Which Make AstraZeneca plc A Sell

Royston Wild reveals why shares in AstraZeneca plc (LON: AZN) are ready to shuttle lower.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am outlining why I believe AstraZeneca (LSE: AZN) (NYSE: AZN.US) is set to experience consistent earnings pressure well into the foreseeable future.

Revenues outlook set to remain poorly

AstraZeneca has seen the effect of patent expirations across a multitude of its key drugs steadily wear down earnings performance in recent years. Although the company is ramping up activity to address this problem, the pharma play is expected to experience ongoing revenues pressure well into the future, and City analysts have pencilled in a 21% earnings per share decline for this year alone.

AstraZeneca has been busy on the acquisition path in recent months as it looks to compensate for a lack of sizeable progress in its organic pipeline. Just this week the firm announced that its Medimmune division, responsible for global biologics research and development, had purchased oncology specialists Spirogen. This follows the purchase of Amplimmune — a developer of therapeutics in cancer immunology — for a fee which could eventually rise to $275m.

Spirogen, which develops high-potency antibody-drug conjugates to fight tumours and cancer, was purchased for an initial $200m, a figure that could rise to $440m depending on certain development milestones being met. AstraZeneca also paid $20m for an equity stake in ADC Therapeutics which currently has a licensing agreement with Spirogen. AstraZeneca has identified oncology as a substantial revenues driver looking ahead.

Still, the full synergies associated with these purchases will of course take time to bed in, while the R&D conveyor belt from these units will require years to develop potential earnings-busters. The same can be said for the pharma giant’s plans to establish a web of research outposts across Europe, which are not expected to significantly boost the firm’s Phase III pipeline until 2016 at the earliest.

And the route from laboratory to pharmacy is a turbulent one, where poor trial results can lead to severe product delays or even the complete abandonment of development in some cases. During the summer AstraZeneca was forced to ditch testing of fostamatinib — an oral spleen tyrosine kinase inhibitor used as an oral treatment for rheumatoid arthritis — after late-stage testing failed to deliver promising results seen during early development. The failure led to a $140m pre-tax impairment charge.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Royston does not own shares in AstraZeneca.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »